Tenaya Therapeutics, Inc. (TNYA) Earnings Call Transcripts

Tenaya Therapeutics, Inc.'s Latest Earnings Call - June 4, 2026

In the second quarter of fiscal year 2026, Tenaya Therapeutics (TNYA:US) showcased significant advancements in its gene therapy programs, particularly TN-201 and TN-401, which target severe forms of heart disease. The company reported promising clinical data, with TN-201 showing reductions in Left Ventricular Mass Index (LVMI) of up to 21% in Cohort 2, indicating meaningful disease modification. Management highlighted upcoming regulatory discussions with the FDA and EMA, which could accelerate the path to pivotal studies, a key catalyst for the stock moving forward.

Reported metrics

Guidance from management

Management indicated that they are on track to provide updates on regulatory discussions with the FDA and EMA in the second half of 2026, signaling potential for accelerated approval pathways.

What analysts pressed on

Analysts expressed concerns regarding the long-term efficacy and safety of the gene therapies, particularly in pediatric populations. Questions were raised about the robustness of the data and the timeline for pivotal study initiation.

Main topics on the call

• Gene Therapy Program Progress — Tenaya's TN-201 and TN-401 gene therapy programs are advancing towards pivotal studies, with TN-201 showing reductions in LVMI of up to 21%. Management stated, "We're quite pleased with what we're seeing in both those co...
• Upcoming Regulatory Updates — Management committed to providing updates on regulatory discussions with the FDA and EMA in the second half of the year, which could facilitate accelerated approvals. They noted, "We're off the races and very pleased wit...
• Collaboration with Alnylam — Tenaya announced a collaboration with Alnylam, involving a $10 million upfront payment and potential milestone payments exceeding $1 billion. This partnership aims to explore genetic targets across various modalities.
• Clinical Data Highlights — Recent data from TN-201 showed significant improvements in disease markers, with 83% of patients transitioning to New York Heart Class I. Management emphasized, "We're seeing durability of the effect even at dose cohort ...

Read the full Tenaya Therapeutics, Inc. transcript (June 4, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 12 Tenaya Therapeutics, Inc. earnings call transcripts on record, spanning March 12, 2024 to August 11, 2026. Based on this history, Tenaya Therapeutics, Inc. reports quarterly. The most recent call on file is dated August 11, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

TNYA

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

12

First call

March 12, 2024

Most recent

August 11, 2026

Reporting cadence

quarterly